- Home
- INSI vs CHRS Comparison
INSI vs CHRS Comparison
Compare INSI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSI
- CHRS
- Stock Information
- Founded
- INSI 1971
- CHRS 2010
- Country
- INSI United States
- CHRS United States
- Employees
- INSI N/A
- CHRS N/A
- Industry
- INSI Investment Managers
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INSI Finance
- CHRS Health Care
- Exchange
- INSI Nasdaq
- CHRS Nasdaq
- Market Cap
- INSI 192.7M
- CHRS 191.3M
- IPO Year
- INSI N/A
- CHRS 2014
- Fundamental
- Price
- INSI $17.02
- CHRS $1.47
- Analyst Decision
- INSI
- CHRS Strong Buy
- Analyst Count
- INSI 0
- CHRS 4
- Target Price
- INSI N/A
- CHRS $5.38
- AVG Volume (30 Days)
- INSI 22.0K
- CHRS 2.4M
- Earning Date
- INSI 01-01-0001
- CHRS 11-06-2024
- Dividend Yield
- INSI 4.90%
- CHRS N/A
- EPS Growth
- INSI N/A
- CHRS N/A
- EPS
- INSI N/A
- CHRS N/A
- Revenue
- INSI N/A
- CHRS $304,340,000.00
- Revenue This Year
- INSI N/A
- CHRS $2.47
- Revenue Next Year
- INSI N/A
- CHRS N/A
- P/E Ratio
- INSI N/A
- CHRS N/A
- Revenue Growth
- INSI N/A
- CHRS 44.19
- 52 Week Low
- INSI $14.28
- CHRS $0.66
- 52 Week High
- INSI $16.40
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- INSI 46.48
- CHRS 50.55
- Support Level
- INSI $16.64
- CHRS $1.35
- Resistance Level
- INSI $17.37
- CHRS $1.77
- Average True Range (ATR)
- INSI 0.29
- CHRS 0.14
- MACD
- INSI 0.03
- CHRS -0.02
- Stochastic Oscillator
- INSI 60.23
- CHRS 28.57
About INSI Insight Select Income Fund
Insight Select Income Fund is a diversified closed-end, management investment company. The fund's investment objective is to seek a high rate of return, primarily from interest income and trading activity, from a portfolio principally consisting of debt securities. It offers various solutions such as risk management, liquidity management, and return generation among others.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.